Leukemia, Myeloid, Accelerated Phase
"Leukemia, Myeloid, Accelerated Phase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
| Descriptor ID |
D015465
|
| MeSH Number(s) |
C04.557.337.539.250.300 C15.378.190.636.370.300
|
| Concept/Terms |
Leukemia, Myeloid, Accelerated Phase- Leukemia, Myeloid, Accelerated Phase
- Leukemia, Myelogenous, Aggressive-Phase
- Leukemia, Myeloid, Accelerated-Phase
- Leukemia, Myeloid, Aggressive-Phase
- Myeloid Leukemia, Chronic, Aggressive-Phase
- Myelogenous Leukemia, Chronic, Aggressive-Phase
- Myeloid Leukemia, Chronic, Accelerated Phase
- Myeloid Leukemia, Chronic, Accelerated-Phase
- Myeloid Leukemia, Chronic, Aggressive Phase
- Leukemia, Myelogenous, Aggressive Phase
- Myelogenous Leukemia, Chronic, Aggressive Phase
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Accelerated Phase".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Leukemia, Myeloid, Accelerated Phase [C04.557.337.539.250.300]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Leukemia, Myeloid, Accelerated Phase [C15.378.190.636.370.300]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Accelerated Phase".
This graph shows the total number of publications written about "Leukemia, Myeloid, Accelerated Phase" by people in this website by year, and whether "Leukemia, Myeloid, Accelerated Phase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, Myeloid, Accelerated Phase" by people in Profiles.
-
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer. 2016 May 01; 122(9):1398-407.
-
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
-
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013 Jul; 98(7):e78-9.
-
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012 Jun; 26(6):1189-94.
-
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
-
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009 May; 94(5):743-4.
-
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18; 113(25):6322-9.
-
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63.
-
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb; 33(2):212-7.
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.